The alliance between Microsoft and immuno-sequencing company Adaptive Biotechnologies can be called "strategic" because it serves all the following strategic purposes except Multiple Choice builds, sustains, or enhances Microsoft's core competence in artificial intelligence. Contracts out certain value chain activities by both parties to outside vendors. Accelerates drug development and bring new therapies to patients sooner than if each party had "gone it alone. " opens up important new healthcare market opportunities for both alliance members. Blocks a competitive threat from Amazon to become a health care industry player